Model N Announces Exercise of Over-Allotment Option

REDWOOD CITY, CA – March 21, 2013 – Model N, Inc. (NYSE: MODN), a provider of revenue management solutions for the life science and technology industries, today announced that the underwriters of [...]

REDWOOD CITY, CA – March 21, 2013 – Model N, Inc. (NYSE: MODN), a provider of revenue management solutions for the life science and technology industries, today announced that the underwriters of its initial public offering exercised in full their option to purchase an additional 1,011,000 shares of common stock from the company. As a result, the total initial public offering size is 7,751,000 shares of common stock, which consists of 7,011,000 shares of common stock to be sold by Model N and 740,000 shares of common stock to be sold by the selling stockholder. All shares sold in the offering are being sold at a price to the public of $15.50. Model N will not receive any proceeds from the sale of shares by the selling stockholders.

J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint bookrunning managers for the offering, and Stifel, Nicolaus & Company, Incorporated, Pacific Crest Securities LLC, Piper Jaffray & Co., and Raymond James & Associates, Inc. are acting as co-managers for the offering.

The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Phone: (866) 803-9204; or Deutsche Bank Securities Inc., 60 Wall Street, New York, New York 10005, Attention: Prospectus Department, by calling (800) 503-4611, or by e-mailing prospectus.cpdg@db.com.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Investor Relations Contact:

ICR for Model N

Greg Kleiner, 650-610-4998


investorrelations@modeln.com



or



Media Contact:

Model N

Kristin Lee, 650-610-4717
Marketing

klee@modeln.com

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N Lists IPO on the New York Stock Exchange – Celebrates First Day as a Publicly-Traded Company

NEW YORK, CA – March 20, 2013 – Redwood Shores, Calif.-based Model N, Inc., a leading revenue management solutions provider to the life science and technology industries, opened for trading today [...]

NEW YORK, CA – March 20, 2013 – Redwood Shores, Calif.-based Model N, Inc., a leading revenue management solutions provider to the life science and technology industries, opened for trading today on the New York Stock Exchange (NYSE) under the ticker symbol “MODN” after its initial public offering. GETCO Securities LLC is the Designated Market Maker for the company’s stock.

Founder, Chairman and CEO Zack Rinat, accompanied by members of Model N’s leadership team, commemorated the company’s first day of trading by ringing the NYSE Opening BellSM and visiting the trading floor to witness the stock opening.

“Becoming a publicly traded company on the NYSE is recognition that Revenue Management software is a proven source of competitive advantage for companies in the life sciences and the technology industries. Furthermore it is a testament to our customers, partners, and employees daring to pioneer a new software category,” said Zack Rinat, Founder, Chairman, and CEO of Model N.

“We are delighted to welcome Model N to the NYSE’s growing community of technology companies,” said Scott R. Cutler, Executive Vice President, Head of Global Listings, NYSE Euronext. “Model N is a leader in revenue management solutions offering life science and technology companies around the globe a suite of innovative tools and services to support their distinctive business needs.  We congratulate Model N on its first day as a publicly-traded company and look forward to sharing a long and fruitful partnership with Model N and its shareholders.”

For more information on NYSE Euronext’s listings business and to learn about trends in the IPO market, please visit the NYSE Euronext IPO Center.

 

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N Announces Pricing of Initial Public Offering

Shares to Trade on NYSE under Ticker Symbol “MODN” REDWOOD CITY, CA – March 19, 2013 – Model N, Inc., a provider of revenue management solutions for the life science and technology [...]

Shares to Trade on NYSE under Ticker Symbol “MODN”

REDWOOD CITY, CA – March 19, 2013 – Model N, Inc., a provider of revenue management solutions for the life science and technology industries, today announced the pricing of its initial public offering of 6,740,000 shares of its common stock, including 6,000,000 shares from the company and 740,000 shares from a selling stockholder, at a price to the public of $15.50 per share. The shares are expected to begin trading on the New York Stock Exchange on March 20, 2013, under the symbol “MODN.” In addition, the company has granted the underwriters a 30-day option to purchase up to 1,011,000 additional shares of common stock.

J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint bookrunning managers for the offering, and Stifel, Nicolaus & Company, Incorporated, Pacific Crest Securities LLC, Piper Jaffray & Co., and Raymond James & Associates, Inc. are acting as co-managers for the offering.

The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Phone: (866) 803-9204; or Deutsche Bank Securities Inc., 60 Wall Street, New York, New York 10005, Attention: Prospectus Department, by calling (800) 503-4611, or by e-mailing prospectus.cpdg@db.com.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Investor Relations Contact:

ICR for Model N

Greg Kleiner, 650-610-4998

investorrelations@modeln.com

or

Media Contact:

Model N

Kristin Lee, 650-610-4717

Marketing

klee@modeln.com

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Revenue Management Leaders from Life Sciences and Technology Companies Recognized for Innovation, Globalization, and Excellence in Analytics

Top Companies Recognized at Model N RAINMAKER for Improving Sales and Overall Organizational Efficiency, Driving Better Financial Results with Revenue Management REDWOOD CITY, CA – March 7, 2013 [...]

Top Companies Recognized at Model N RAINMAKER for Improving Sales and Overall Organizational Efficiency, Driving Better Financial Results with Revenue Management

REDWOOD CITY, CA – March 7, 2013 – Model N, Inc., Model N announced yesterday the recipients of theRAINMAKER Awards at its ninth annual Global Revenue Management summit in Phoenix, AZ. Each year, Model N recognizes the companies that have driven tremendous results by transforming their business processes, for innovation and globalization of Revenue Management. The recipients for the 2013 RAINMAKER Awards are:

Corning Life Sciences

Revenue Management Visionary

Abbot Diabetes Care

Revenue Management Best Practices

Nokia

Revenue Management Globalization

Salix Pharmaceuticals

Revenue Management Innovation

Allergan

Revenue Management Analytics

Micron

Revenue Management Passion for the Journey

The RAINMAKER Awards were presented yesterday during the conference’s Welcome Address to an audience of over 400 Life Sciences and Technology executives and professionals.

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Global Revenue Management Providing Life Sciences and Technology Companies with the Architectural Blueprint Needed for Maximizing Revenue

Record Number of Life Sciences and Technology Companies Gather at Model N RAINMAKER 2013, Bringing Sales Effectiveness, Global Responsiveness, Channel Performance, and Regulatory Compliance to [...]

Record Number of Life Sciences and Technology Companies Gather at Model N RAINMAKER 2013, Bringing Sales Effectiveness, Global Responsiveness, Channel Performance, and Regulatory Compliance to the Forefront of Discussion for Revenue Management Leaders

REDWOOD SHORES, CA – March 6, 2013 – RAINMAKER 2013 – Model N, Inc., Model N’s ninth-annual Global Revenue Management summit, opened today at the Arizona Biltmore in Phoenix to a sellout crowd of Life Science and Technology leaders and innovators. The theme of this year’s event — Architecting Revenue — points to how Model N’s Revenue Management systems are providing companies with the blueprint needed for maximizing revenue. This year’s attendees and speaker lineup features experts from across both industries, representing close to100 top Life Sciences and Technology organizations and companies.

Architecting a Global Revenue Management Foundation

In the welcome address this morning, President and CEO, Zack Rinat showcased Model N’s milestones from the past year including a record number of customer go-lives and a positive outlook for the growth of Revenue Management in the coming year. Co-founder & Vice President of Analytics, Ali Tore, followed with a breakdown of industry trends that are driving continual investment in Global Revenue Management solutions within Life Sciences and Technology companies. Highlights included:

  • The launch of Model N International Reference Pricing Solution for Life Sciences Manufacturers for building a truly Global Revenue Management foundation
  • Record number of go lives over the last 12 months with 39 for 25 customers across the Life Sciences and the High Tech sectors
  • Significant expansion of Revenue Management Intelligence with investments in two of Model N’s key analytics products, Price ImpACT and Channel ImpACT
  • Release of Field ImpACT Mobile, Model N’s first product designed and optimized for the iPad to be used in multiple mobile scenarios by Pharmaceutical sales reps
Business Tracks for Driving Success

RAINMAKER 2013 will deliver industry insights and best practices to attendees through a new agenda format of business tracks, aligned with the business processes and value themes that are top of mind for Life Sciences and Technology leaders.

Featured Sessions
  • Health Care in the 21st Century: The Case For Global Revenue Management with Abbott Diabetes Care, Abbott Diagnostics Division, and HighPoint Solutions
  • Teardown Live! with IHS, a live breakdown of a consumer electronic to understand the underlying price and channel implications
  • Pricing Panel: Central vs. Regional Pricing Organization with Auxilium Partners, Maxim Integrated, Linear Technology, ON Semiconductor, NXP, and CSR
  • From Dx to Rx: Why Reform Makes Collaboration Critical for Manufacturer Success with Truven Health Analytics
  • Industry Leader Panel: Pricing to Profitability with Corning Life Sciences, and Deloitte Consulting
  • Industry Leader Panel: Maximizing Managed Markets with IMS Health, Johnson & Johnson, and Actelion
  • Determining Opportunity Value Using TAM not Volume with Atmel
  • Optimizing Design Win Tracking and Aligning the Sales Force with Cirrus Logic
  • Regulatory State of the State 2013 for Biopharma and Med Tech with King & Spalding
  • Industry Leader Panel: Regulatory Compliance with King & Spalding, IMS Health, and Johnson & Johnson
  • The Gross-To-Net Advantage: Minimizing Financial Risk with Medicis
  • New Trends for Ship & Debit in Asia with McKinsey & Company
  • Industry Leader Panel: Extracting the Data You Need from the Channel with Atmel, McKinsey & Company, PMC-Sierra, and Linear Technology
Special Guest and Keynote Sessions
  • RAINMAKER Keynote, Geoff Colvin, Senior Editor at Large, FORTUNE, who will speak on trends in the global economy affecting Revenue Management
  • “Whose Revenue Is It Anyway?” with Greg Proops and Jeff Davis of “Whose Line is it Anyway?” fame
Record Investment from Industry Sponsors

RAINMAKER 2013 has received an unprecedented level of sponsorships, showcasing the prominent role Model N’s ecosystem partners are playing in delivering value to Model N customers. The Partner Pavilion features the largest number of exhibiting implementation and technology experts in the Life Sciences and High Tech industries at RAINMAKER.

  • Global Strategic Implementation Sponsor: HighPoint Solutions
  • Strategic Implementation Sponsor, Gaining Insights Track: Alliance Life Sciences
  • Strategic Implementation Sponsor, Managed Markets Track: IMS Health
  • Strategic Implementation Sponsor, Optimizing Model N Track: Mindlance Life Sciences
  • Sponsor, Pricing to Profitability Track: Deloitte Consulting
  • Strategic Advisory Sponsor, Med Tech Compliance: Huron Consulting Group
  • Ecosystem Sponsor: Oracle

Model N’s semi-annual customer and executive advisory board meetings will also be held concurrently at RAINMAKER 2013.

“Economic uncertainty is reshaping how companies think about competitiveness, core enterprise processes, and growth,” noted Ken Pulverman, VP of Corporate Marketing, Model N. “Our RAINMAKER attendees look to this conference and Model N for the most current thinking on how to most effectively manage their revenue generation and revenue risk management processes.“

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Pharma Leaders Boost Sales Productivity with Latest iPad Ready, Mobile Solution from Model N

Recent Release of Model N Field ImpACT is Designed and Optimized for Use in Multiple Mobile Scenarios REDWOOD SHORES, CA – March 5, 2013 – Model N today announced the launch of a unified solution [...]

Recent Release of Model N Field ImpACT is Designed and Optimized for Use in Multiple Mobile Scenarios

REDWOOD SHORES, CA – March 5, 2013 – Model N today announced the launch of a unified solution for web, CRM, and mobile with its latest release of Field ImpACT, a powerful cloud-based analytics solution that creates a shared understanding of sales performance and competitive threats for Pharma sales executives and field representatives. This is the first Model N solution with native mobile capability and is specifically targeted for use on the iPad. This year, Gartner predicts that at least 85% of Pharma sales reps will be using an iPad in the field. A Fortune 500 biopharma manufacturer and Model N customer has recently deployed Field ImpACT to hundreds of its sales reps.

Field ImpACT Highlights

Field ImpACT, accessed on the iPad, helps Pharma sales reps to more effectively plan their week, whether on the road or in the office, by highlighting which prescribers to visit based on the effectiveness of calling, sampling and targeted campaigns, and by also showing how payer dynamics are affecting prescription behavior. The mobile component to this solution now allows for faster ramp up of reps’ field responsiveness with easier access to the same robust insights once only accessed on a laptop or desktop. Additional features from the Field ImpACT release include:

  • Offline access to data
  • Distilled analytics, not just “charts and graphs”
  • Customizable account breakdown for each rep and their brands
  • “Danger” accounts distribution based on prescribing behavior
  • At-risk trend indicator setting for each target brand
  • Support of standards based Single Sign-On (SSO) to common CRM systems

“Model N’s latest release of Field ImpACT with mobile capability showcases our commitment to innovating the way sales leaders and field reps consume their business data,” says Ali Tore, Co-Founder and VP of Analytics at Model N. “We’ve allowed access to and presented the data in a way that directly addresses the business questions that drive revenue potential and sales productivity in the field.”

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.